Additionally, a rebiopsy is necessary not only for patients with EGFR mutation-positive NSCLC to detect T790M, but also for analysing ALK rearrangement, PD-L1 TPS, and aberrations in BRAF and ROS1, and to detect other genes including using NGS. This evidence concerns the gene EGFR and non-small cell lung carcinoma.